Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
Purity > 98.00%
|Preparation method||In a cytomegalovirus (CMV)-restimulation assay, 2 × 10^5 PBMCs from a CMV-positive donor (Astarte) were stimulated using lysate of CMV-infected cells (Astarte), with serial dilutions of nivolumab added at the initiation of the assay. After 4 days, supernatants were assayed for IFNγ.|
|Incubation time||4 days|
|Animal models||Cynomolgus monkeys (Macaca fascicularis)|
|Dosages||3 mg/kg or 10 mg/kg|
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
Animal A (mg/kg) = Animal B (mg/kg) multiplied by Animal B Km
Animal A Km
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Kmfactor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg
Nivolumab is a programmed death-1 (PD-1) blocking antibody used to treat advanced (metastatic) non-small cell lung cancer.
Nivolumab binds to PD-1-expressing CHO cells with an EC50 of 1.66 nM, but not to the parental CHO cell line. Nivolumab binds to PD-1 on activated T cells with EC50 of 0.64 nM. Nivolumab also inhibits the interaction between PD-1 and its ligands PD-L1 and PD-L2 with IC50 values of 2.52 and 2.59 nM, respectively. Nivolumab (1.5 ng/mL) enhances T cell responsiveness in the presence of T cell receptor stimulation .
Nivolumab (10 and 50 mg/kg, i.v.) was well tolerated in cynomolgus monkeys. In females treated with 50 mg/kg, serum chemistry changes were limited to a 28% reversible reduction in T3 at week 13. T4 and TSH levels were unchanged. There were no changes in T3, T4 or TSH levels in males treated with 50 mg/kg. Nivolumab exposure increased in a roughly dose-proportional manner between 10 and 50 mg/kg, with no significant gender differences .
. Wang C, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunity Research. 2014 Sep;2(9):846-56.
|Synonyms||BMS-936558, ONO-4538, MDX-1106|
|Solubility||N/A||Storage||Store at -20°C|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5(Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *